Showing results (191-200 of 219) with videos related to
Sort By:
Pageof 22
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2023
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic LeukemiaJohn N Allan, Ian W Flinn, Tanya Siddiqi, et al.Journal of Clinical Apheresis|March 12, 2021
Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantationSrinivasa Reddy Sanikommu, Emily S Reese, Jiaxian He, et al.American Journal of Hematology|October 20, 2017
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphomaYasmin Abaza, Hagop M Kantarjian, Stefan Faderl, et al.Blood Cancer Journal|October 22, 2024
The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemiaRonghua Zhang, Priyanka Khare, Priyanka Banerjee, et al.Cancer|June 14, 2017
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimensRashmi Kanagal-Shamanna, Preetesh Jain, Koichi Takahashi, et al.American Journal of Hematology|March 15, 2020
Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemiaKoji Sasaki, Hagop Kantarjian, William Wierda, et al.The New England Journal of Medicine|May 30, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, Michael Keating, Philip Thompson, et al.Blood and Lymphatic Cancer : Targets and Therapy|September 18, 2020
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial TherapyChaitra Ujjani, Anthony Mato, Brian T Hill, et al.Blood|February 23, 2022
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortConstantine S Tam, John N Allan, Tanya Siddiqi, et al.Pageof 22